USA News
Worldwide revenue of $53.2 million – a decrease of 1.4% year over year U.S. revenue of $43.5 million – an increase of 1.1% year over year International revenue of $9.8 million – a decrease of 11.0% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 29, 2020-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences.
MASON, Ohio --(BUSINESS WIRE)--Apr. 15, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020 .
MASON, Ohio --(BUSINESS WIRE)--Apr. 13, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the
MASON, Ohio --(BUSINESS WIRE)--Apr. 9, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 18, 2020-- AtriCure, Inc .
MASON, Ohio --(BUSINESS WIRE)--Feb. 3, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it
MASON, Ohio --(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio --(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio --(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)
© 2022 Atricure, Inc. All Rights Reserved.
